Effects of the association of lansoprazole, clarithromycin and metronidazole for Helicobacter pylori eradication therapy, measured by the 13C Aminopyrlne breath test

Medical Science Monitor

Volumn 11, Issue 2, 2005, Pages

  Malfatti, Federica ^a   Giannini, Edoardo ^a   Testa, Emanuela ^a   Polegato, Simone ^a   Podestà, Elena ^a   Fumagalli, Alessandra ^a   Cotelessa, Tiziana ^a   Chiarbonello, Bruno ^a   Bellotti, Michele ^a   Botta, Federica ^a   Milazzo, Sara ^a   Testa, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

13C ABT; Clarithromycin; Helicobacter pylori; Lansoprazole; Liver function; Metronidazole

Indexed keywords

AMINOPHENAZONE; CARBON 13; CARBON DIOXIDE; CLARITHROMYCIN; CYTOCHROME P450; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; AMINOPHENAZONE BREATH TEST; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; DRUG EFFECT; DRUG USE; ENZYME ACTIVITY; ERADICATION THERAPY; EVALUATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER FUNCTION; MALE; RANK SUM TEST; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGE FACTORS; AGED; AMINOPYRINE; BREATH TESTS; CARBON ISOTOPES; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; SEX CHARACTERISTICS;

EID: 13844253468     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Radys W, Korzon M, Bielanski W et al.: Familial occurrence of Helicobacter pylori infections. Med Sci Monit, 2003; 9(Suppl.4): 29-33
2. The European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter Pylori infection: The Maastricht Consensus Report. Gut, 1997; 41: 8-13
3. Harris A: Current regimes for treatment of Helicobacter Pylori infection. Br Med Bull, 1998; 54: 195-205
4. Andrzejewska E, Szkaradkiewicz A, Klincewicz H et al.: Characterization of Helicobacter pylori strains isolated before and after therapy. Med Sci Monit, 2003; 9: 400-4
5. Deltenre M, Ntounda R, Jonas C et al: Eradication of Helicobacter pylori: why does it fail? Ital J Gastroenterol Hepatol, 1998; 30: 326-28
6. Hunt RH, Cederberg C, Dent J et al: Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci, 1995; 40: 24-49
7. Bell NJV, Hunt RH: Role of gastric suppression in the treatment of gastro-oesophageal reflux disease. Gut, 1992; 33: 118-24
8. Sachs G: Proton pump inhibitors and acid-related diseases. Pharmacology, 1997; 17: 22-37
9. Adachi K, Katsube T, Kawamura A: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther, 2000; 14: 1259-66
10. Goodwin CS, Mendall MM, Northfield TC: Helicobacter pylori infection. Lancet, 1997; 349: 265-69
11. Grayson ML, Eliopoulos GM, Ferraro MJ et al: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis, 1989; 8: 888-89
12. Goddard AF, Jessa MJ, Barrett DA et al: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology, 1996; 111: 358-67
13. Hadebakk JG, Berstad A: Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinetic, 1996; 31: 386-406
14. Curi-Pedrosa R, Pichard L, Bonfils C et al: Major implication of cytochrome P450 3A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br J Clin Pharmacol, 1993; 36: 156P
15. Byrne MF, Murray FE: Formulary management of proton pump inhibitors. Pharmacoeconomics, 1999; 16: 225-46
16. Sagir A, Schmitt M, Dilger K et al: Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion, 2003, 68: 41-48
17. Mensa J, Garcia-Vazquez E, Vila J: Macrolides, ketolides and streptogramins. Enferm Infect Microbiol Clin, 2003; 21: 200-7
18. Perri F, Pastore M, Annese V et al: The aminopyrine breath test. Ital J Gastroenterol, 1994; 26: 306-17
19. Giannini E, Romagnoli P, Fasoli A et al: Influence of Helicobacter pylori eradication therapy on 13c-aminopyrine breath test: comparison among omeprazole-, lansoprazole- or pantoprazole-containing regimens. Am J of Gastroenterol, 2000; 95: 2762-67
20. Merkel C, Bolognesi M, Bellon S et al: Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut, 1992; 33: 836-42
21. 13C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther, 2002; 16: 717-25
22. Welage LS, Berardi RR: Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc, 2000; 40: 52-62
23. Reilly JP: Safety profile of the proton-pump-inhibitors. Am J Health Syst Pharm, 1999; 56: S11-17
24. Curi-Pedrosa R, Daujat M, Pichard L et al: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther, 1994; 269: 384-92
25. Bowen WP, Carey JE, Miah A et al.: Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos, 2000; 28: 781-88
26. Ito K, Ogihara K, Kanamitsu S et al.: Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos, 2003; 31: 945-54
27. Ushiama H, Echizen H, Nachi S, Ohnishi A: Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter Pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther, 2002; 72: 33-43
28. Loft S, Otton SV, Lennard MS et al: Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol, 1991; 41: 1127-34
29. Ammon S, Treiber G, Kees F et al: Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol Ther, 2000; 14: 759-66
30. Marshall BJ: Helicobacter pylori. Am J Gastroenterol, 1994; 89: 116-28
31. 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis. Hepato-Gastroenterol. 2000; 47: 234-38
32. Branch RA: Drugs as indicators of hepatic function. Hepatology, 1982; 2: 97-105
33. Reichen J, Bianchi L, Frei PC et al: Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B, Results of a randomized multicentric trial. Swiss Association for Study of the Liver. J Hepatol, 1994; 20: 168-74
34. Horsmans Y, Brenard R, Geubel AP: Short report: interferon alpha decreases C-aminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther, 1994; 8: 353-55